Skip to content

evaluation of the effect of Coritrip on the improvement of symptoms of gastroesophageal reflux disease

Comparison of the effect of Coritrip and omeprazole on the improvement of symptoms of gastroesophageal reflux disease: a controlled randomized, double-blind, double-arm parallel trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221102056376N1
Enrollment
76
Registered
2023-01-07
Start date
2023-02-20
Completion date
Unknown
Last updated
2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroesophageal reflux disorder. Gastro-esophageal reflux disease with esophagitis

Interventions

Intervention 1: Intervention group: One capsule of placebo half an hour before breakfast, one capsule of coriander after lunch and one capsule of coriander after dinner. Intervention 2: Control group:

Sponsors

Fasa University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Organic causes of indigestion have been ruled out by the doctor. Do not have a history of allergy to medicinal plants used in this study. Not pregnant or breastfeeding and not planning to become pregnant during the study. Do not have chronic liver, kidney or cancer diseases. Not taking anticoagulant drugs such as warfarin, plavix, aspirin and other chemical or herbal drugs that interfere with the studied compound or disrupt the results of the plan. The patient has been diagnosed with GERD by a doctor during endoscopy. Having ROME IV criteria to enter the study

Exclusion criteria

Exclusion criteria: Incidence of drug allergy Diagnosis of organic dyspepsia during study The patient's unwillingness to continue the plan Starting to take drugs such as anticoagulants such as warfarin, Plavix, aspirin and other drugs that interfere with the herbs in the composition or have a possible positive or negative effect on functional indigestion. Pregnancy contracting covid19 or any disease for which the doctor required the patient to withdraw from the plan. The location of the study is the clinic and office of internal medicine and gastroenterology specialists in Fasa city.

Design outcomes

Primary

MeasureTime frame
Quality of life (SF-36 questionnaire). Timepoint: 30, 60 days from the first day of study. Method of measurement: SF-36 questionnaire.;Abdominal bloating intensity and rate, early satiety rate, stomach rumbling rate and burping rate. Timepoint: 30, 60 days from the first day of study. Method of measurement: questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFasa University of Medical Sciences

Fasa University of Medical Sciences

ftorabi7413@yahoo.com+98 71 5335 0994

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026